The molecular and cellular biologic basis for the radiation treatment of benign proliferative diseases.
Since its discovery, radiation has been used to treat numerous ailments, including many benign conditions. The most susceptible disorders have included keloids, heterotopic bone formation, and, most recently, vascular restenosis. These disorders are proliferative in nature and fall under the category of excessive wound healing or scar formation after trauma. In addition, radiation has been used for its immunosuppressive quality, eg, in organ transplantation to suppress graft rejection and in the treatment of autoimmune diseases. In this article, we have chosen keloids as an archetype for radiation use with benign conditions; the radiation inhibition of vascular restenosis will be used as a prototype to explore a paradigm for the molecular and cellular basis of radiation treatment for selected benign disorders. Vascular restenosis is currently one of the new frontiers of radiation therapy and offers opportunities to explore the role of inflammatory or immune cell responses in benign conditions that lead to excessive fibrogenesis and require treatment. The pathophysiology of surgical wound healing has not been avidly studied in the radiobiologic laboratory setting. However, the paradigm we propose for the effectiveness of radiation treatment for benign conditions is based on the model offered by Clark. He describes three phases of molecular and cellular events in which an inflammatory phase precedes the fibrogenic phase, occurs within hours of injury, and continues for weeks. We postulate that the radiosensitive targets within the vascular milieu are the monocyte/macrophages that would otherwise act as the trigger for the induced cytokine cascade, leading to the myofibroblast being recruited from a quiescent to a proliferative phase, resulting in fibrogenesis.
Rubin
P
P
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Soni
A
A
Williams
J P
JP
D003251:Constriction, Pathologic / Q000532:radiotherapy; D006801:Humans; D007627:Keloid / Q000532:radiotherapy*; D008264:Macrophages / Q000502:physiology; D009000:Monocytes / Q000502:physiology; D016491:Peripheral Vascular Diseases / Q000532:radiotherapy*; D012008:Recurrence; D014945:Wound Healing